• 1. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381
• 2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 3. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 4. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 5. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977

Research Briefing on 6-Bromo-5-fluoro-3-iodo-1-methyl-1H-indazole (CAS: 1286734-96-0) and Its Applications in Chemical Biology and Pharmaceutical Research

The compound 6-bromo-5-fluoro-3-iodo-1-methyl-1H-indazole (CAS: 1286734-96-0) has emerged as a key intermediate in the synthesis of biologically active molecules, particularly in the development of kinase inhibitors and other therapeutic agents. Recent studies highlight its utility in medicinal chemistry due to its versatile reactivity and potential for selective functionalization. This briefing synthesizes the latest research on this compound, focusing on its synthetic applications, biological relevance, and emerging therapeutic potentials.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of 6-bromo-5-fluoro-3-iodo-1-methyl-1H-indazole as a precursor in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The compound's halogen-rich structure allows for efficient cross-coupling reactions, enabling the rapid generation of diverse analogs for structure-activity relationship (SAR) studies. Researchers at Pfizer reported a 40% improvement in yield compared to traditional routes when using this intermediate in their BTK inhibitor program.

In cancer research, this indazole derivative has shown particular promise. A team at Memorial Sloan Kettering Cancer Center recently utilized it to develop a new class of FLT3 inhibitors for acute myeloid leukemia (AML) treatment. The 5-fluoro and 3-iodo substituents were found to be critical for target engagement, with crystallography studies revealing unique interactions with the FLT3 kinase domain. These findings were published in Nature Chemical Biology (2024) and have sparked interest in further derivatization of this scaffold.

The compound's stability profile has also been investigated in depth. A 2024 European Journal of Pharmaceutical Sciences paper reported excellent thermal stability (decomposition temperature >200°C) and favorable solubility in common organic solvents, making it particularly suitable for high-throughput screening approaches. These physicochemical properties, combined with its synthetic versatility, position 1286734-96-0 as a valuable building block in drug discovery pipelines.

Emerging applications extend beyond oncology. Recent work at Stanford University has explored its use in developing positron emission tomography (PET) tracers, leveraging the radioisotope exchange potential of the 3-iodo position. Preliminary results suggest promising imaging properties for neurological targets, potentially opening new avenues in diagnostic agent development.

As research progresses, safety and scalability considerations have come to the forefront. A 2023 white paper from the American Chemical Society's Green Chemistry Institute highlighted improved synthetic routes to 6-bromo-5-fluoro-3-iodo-1-methyl-1H-indazole that reduce heavy metal waste by 60% compared to earlier methods. These advances address both environmental concerns and the need for cost-effective production at commercial scales.

The compound's future appears bright, with several pharmaceutical companies listing derivatives in their preclinical pipelines. Ongoing research continues to uncover new applications for this versatile scaffold, particularly in targeted protein degradation and covalent inhibitor design. As the field moves toward more complex therapeutic modalities, 1286734-96-0 and its derivatives are likely to play an increasingly important role in medicinal chemistry innovation.

• 2432848-78-5(6-Bromo-7-fluoro-3-iodo-1H-indazole)
• 1257535-07-1(4-Fluoro-3-iodo-1-methyl-1H-indazole)
• 865156-35-0(5-bromo-3-iodo-2-methyl-2H-indazole)
• 1082041-88-0(5-Bromo-4-fluoro-3-iodo-1H-indazole)
• 1286734-77-7(6-bromo-5-fluoro-3-iodo-1h-indazole)
• 865156-34-9(1H-INDAZOLE, 5-BROMO-3-IODO-1-METHYL-)
• 633335-82-7(5-Bromo-6-fluoro-3-iodo-1H-indazole)
• 1257535-15-1(6-fluoro-3-iodo-1-methyl-1h-indazole)
• 1060817-10-8(5-Fluoro-3-iodo-1-methyl-1H-indazole)
• 1260741-78-3(6-Bromo-3-iodo-1-methyl-1H-indazole)